dalteparin has been researched along with Myasthenia Gravis in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schinzel, H | 1 |
| Berghoff, K | 1 |
| Beuermann, I | 1 |
| Sauer, O | 1 |
| von Mach, MA | 1 |
| Weilemann, LS | 1 |
1 trial available for dalteparin and Myasthenia Gravis
| Article | Year |
|---|---|
Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience.
Topics: Adult; Anticoagulants; Dalteparin; Guillain-Barre Syndrome; Humans; Monitoring, Physiologic; Myasthe | 2006 |